February ’21 Newsletter
While we are no means out of the woods, the FDA’s analysis this week of Johnson & Johnson’s COVID-19 single-dose vaccine is more good news that points to the gradual return to normal life. Throughout the crisis, the health care industry’s response to COVID 19 has been one of resilience, persistence, and commitment on the part of care providers and innovation and collaboration among researchers and developers. It has been a difficult time but was an amazing opportunity for every corner of the healthcare industry — from early and late-stage developers to front-line workers — to demonstrate that healthcare is not just an industry but a calling to improve the quality and length of people’s lives.
Pre-pandemic, transformative technologies like artificial intelligence, at-home diagnostics and virtual care were expected to gain gradual traction through 2020 and beyond. However, last year’s unexpected events swiftly increased the rate of adoption for these and other new technologies, significantly shifting industry trends and accelerating the pace of change.
Bioverge is likewise preparing for some major activities this year, which we will be able to share with you soon. In the meantime, we’re happy to announce some early wins for the year. First, I’m pleased to announce that — after vetting and selection by a review committee — I have been accepted into Forbes’s Finance Council, an invitation-only community for executives from which I will be able to share the Bioverge perspective on this exciting industry on Forbes.com.
Further, I am delighted to announce that Bioverge was ranked #2 in TechRound’s Fintech50. The announcement follows a week of judging from an expert panel including Sharon Miles and Simon Rabin of Chip, Jelle Pol of Dusk Network and Paula Grynczel of Capital on Tap.
As you’ll see in the news, our portfolio companies have also been active. It has been a challenging year, but the life science sector emerges into 2021 with exciting prospects and a renewed mission.
Sincerely,
Neil, Bioverge CEO
